Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Aug 24, 2023
MiNK Therapeutics to Participate in September Investor Conferences
NEW YORK , Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
Aug 10, 2023
MiNK Therapeutics Reports Second Quarter 2023 Results
-  Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center -  iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid Tumor Cancers and in Respiratory Distress -  MiNK-215, a Novel FAP-CAR-iNKT Cell Therapy ,
Corporate Presentation

SEC Filings

Form Description Filing date View
4

Statement of changes in beneficial ownership of securities

 View HTML
0000950170-23-050807.pdf
0000950170-23-050807.rtf
0000950170-23-050807.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000950170-23-046775.pdf
0000950170-23-046775.rtf
0000950170-23-046775.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000950170-23-046773.pdf
0000950170-23-046773.rtf
0000950170-23-046773.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000950170-23-046774.pdf
0000950170-23-046774.rtf
0000950170-23-046774.xls

Data provided by Kaleidoscope.

Events and Presentations